OA-07 Trial: Lorecivivint's Role in Knee Osteoarthritis Management - EMJ

OA-07 Trial: Lorecivivint’s Role in Knee Osteoarthritis Management

1 Mins

FINDINGS from the Phase III trial, OA-07, were presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO IOF-ESCEO) 2024, held in London, UK. OA-07 served as a crucial extension of the lorecivivint investigation, focusing on its efficacy in treating knee osteoarthritis (OA) for a period of 2 years. Lorecivivint, a potential CLK/DYRK inhibitor, targets inflammatory and Wnt pathways implicated in OA progression.

Following the Phase II success and subsequent Phase III setbacks, OA-07 aimed to provide further insight into lorecivivint’s long-term effects. Patients from the previous OA-11 trial, comprising individuals with varying degrees of OA severity, were recruited for OA-07. Notably, roughly half of the OA-11 participants chose to continue into OA-07, indicating sustained interest and commitment to the study.

In OA-07, patients received a second dose of lorecivivint injection and continued their original randomisation, with both investigators and patients initially blinded to treatment. In the third year, all the patients moved to the open-label phase. The trial’s primary objective was to assess changes in medial joint space width over the course of the study. This measure serves as a critical indicator of structural progression or stability in knee OA.

Results from OA-07 revealed that lorecivivint, over the 2-year period, demonstrated a significant stabilisation of joint space width compared to placebo, indicating a potential disease-modifying effect. This study’s findings suggest that lorecivivint could effectively slow down the structural deterioration associated with knee OA, offering hope for patients facing this debilitating condition.

Moreover, patient-reported outcomes, including pain and function, showed improvement with lorecivivint treatment. This improvement was particularly pronounced in patients with earlier-stage OA, highlighting the importance of early intervention in managing the disease.

This study underscored the potential of lorecivivint as a viable treatment option for knee OA. Its ability to stabilise the joint structure, and improve symptoms over a significant period, suggests long-term efficacy and safety, paving the way for further investigation and potential clinical application in addressing this prevalent and challenging condition.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?